Antisense therapy for cancer

Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans

1998 • 14,674 citations

Jak-STAT Pathways and Transcriptional Activation in Response to IFNs and Other Extracellular Signaling Proteins

1994 • 5,932 citations

Insulin-Like Growth Factors and Their Binding Proteins: Biological Actions*

1995 • 4,419 citations

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

1997 • 3,167 citations

Bcl-2 and the regulation of programmed cell death

1994 • 2,346 citations

The STATs of cancer — new molecular targets come of age

2004 • 2,232 citations

X-linked IAP is a direct inhibitor of cell-death proteases

1997 • 1,961 citations

Control of apoptosis and mitotic spindle checkpoint by survivin

1998 • 1,881 citations

IAP proteins: blocking the road to death's door

2002 • 1,753 citations

Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.

1978 • 1,668 citations

Insulin-like growth factors and neoplasia

2004 • 1,452 citations

IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs.

1998 • 1,243 citations

Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.

1986 • 1,118 citations

Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer.

1992 • 1,063 citations

Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention.

2002 • 1,027 citations

Pathways of apoptotic and non-apoptotic death in tumour cells

2004 • 1,026 citations

The inhibitors of apoptosis (IAPs) and their emerging role in cancer

1998 • 985 citations

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

1995 • 945 citations

Regulation of protein kinase C

1997 • 919 citations

Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line

1993 • 898 citations

Survivin, versatile modulation of cell division and apoptosis in cancer

2003 • 880 citations

RNAi-mediated pathways in the nucleus

2005 • 839 citations

Evaluation of 2‘-modified oligonucleotides containing 2‘-deoxy gaps as antisense inhibitors of gene expression

1993 • 734 citations

LNA (Locked Nucleic Acid): High-Affinity Targeting of Complementary RNA and DNA

2004 • 676 citations

STAT proteins: novel molecular targets for cancer drug discovery

2000 • 634 citations

Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression

2001 • 617 citations

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

1999 • 613 citations

Biological and Clinical Implications of Heat Shock Protein 27000 (Hsp27): a Review

1993 • 551 citations

Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flow

2004 • 546 citations

Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.

1995 • 537 citations

Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.

2002 • 526 citations

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1997 • 502 citations

Inhibitor of Apoptosis Proteins: Translating Basic Knowledge into Clinical Practice

2004 • 499 citations

HSP27 inhibits cytochrome c‐dependent activation of procaspase‐9

1999 • 496 citations

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1998 • 496 citations

On the role of Hsp27 in regulating apoptosis.

2003 • 494 citations

Chemosensitisation of malignant melanoma by BCL2 antisense therapy

2000 • 487 citations

Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation.

1990 • 485 citations

Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas.

1998 • 473 citations

Molecular chaperones and the cytoskeleton

1997 • 462 citations

Phase I Clinical and Pharmacokinetic Study of Bcl-2 Antisense Oligonucleotide Therapy in Patients With Non-Hodgkin’s Lymphoma

2000 • 460 citations

Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase

1996 • 444 citations

A review of issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides

1999 • 441 citations

Clusterin Has Chaperone-like Activity Similar to That of Small Heat Shock Proteins

1999 • 438 citations

Hsp27 as a Negative Regulator of Cytochrome c Release

2002 • 429 citations

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells

2002 • 420 citations

A public database for gene expression in human cancers.

1999 • 417 citations

Selective depletion of heat shock protein 70 (Hsp70) activates a tumor-specific death program that is independent of caspases and bypasses Bcl-2

2000 • 393 citations

A Critical Role for Stat3 Signaling in Immune Tolerance

2003 • 388 citations

Clusterin is a secreted mammalian chaperone

2000 • 365 citations

Heat shock proteins, cellular chaperones that modulate mitochondrial cell death pathways

2003 • 363 citations

Heat shock protein expression independently predicts clinical outcome in prostate cancer.

2000 • 361 citations

Hormone Therapy Failure in Human Prostate Cancer: Analysis by Complementary DNA and Tissue Microarrays

1999 • 356 citations

Mcl-1, a Bcl-2 Family Member, Delays the Death of Hematopoietic Cells Under a Variety of Apoptosis-Inducing Conditions

1997 • 336 citations

Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs

2004 • 312 citations

Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer

2004 • 305 citations

Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells

2001 • 304 citations

Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy

1998 • 297 citations

Geldanamycin as a Potential Anti-Cancer Agent: Its Molecular Target and Biochemical Activity

1999 • 297 citations

MCL-1S, a Splicing Variant of the Antiapoptotic BCL-2 Family Member MCL-1, Encodes a Proapoptotic Protein Possessing Only the BH3 Domain

2000 • 273 citations

Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: Transforming ability and frequent detection in human cancer

1996 • 272 citations

MCF-7 breast cancer cells transfected with protein kinase C-alpha exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype.

1995 • 269 citations

Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.

2001 • 265 citations

Androgen‐repressed messages in the rat ventral prostate

1986 • 261 citations

HSP27 and HSP70: Potentially Oncogenic Apoptosis Inhibitors

2003 • 249 citations

Apolipoprotein J (clusterin) and Alzheimer's disease

2000 • 243 citations

Inhibition of protein kinase C-alpha expression in mice after systemic administration of phosphorothioate antisense oligodeoxynucleotides.

1994 • 242 citations

Overexpression of Clusterin in Human Breast Carcinoma

2000 • 242 citations

HSP27 as a mediator of confluence-dependent resistance to cell death induced by anticancer drugs.

1997 • 238 citations

Antisense oligonucleotide-based therapeutics for cancer

2003 • 230 citations

Testosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancer.

2000 • 228 citations

Prevention of cell death induced by tumor necrosis factor alpha in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin).

1995 • 224 citations

Hsp27 Inhibits Cytochrome c-Mediated Caspase Activation by Sequestering Both Pro-caspase-3 and Cytochrome c

2001 • 220 citations

Antisense oligonucleotides targeting XIAP induce apoptosis and enhance chemotherapeutic activity against human lung cancer cells in vitro and in vivo.

2003 • 220 citations

Clusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapy

2002 • 218 citations

Specific Inhibition of PTEN Expression Reverses Hyperglycemia in Diabetic Mice

2002 • 216 citations

Down-regulation of Survivin by Antisense Oligonucleotides Increases Apoptosis, Inhibits Cytokinesis and Anchorage-Independent Growth

2000 • 205 citations

Silencing Expression of the Clusterin/Apolipoprotein J Gene in Human Cancer Cells Using Small Interfering RNA Induces Spontaneous Apoptosis, Reduced Growth Ability, and Cell Sensitization to Genotoxic and Oxidative Stress

2004 • 205 citations

Stress-induced transcription of the clusterin/apoJ gene

1997 • 196 citations

Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer.

1997 • 195 citations

A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer.

2001 • 189 citations

Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice.

1999 • 188 citations

Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy

2003 • 188 citations

Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries

1998 • 188 citations

Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas

2000 • 179 citations

Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model.

1999 • 176 citations

Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer

1999 • 174 citations

Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.

2000 • 171 citations

A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.

2000 • 156 citations

Immunohistochemical Analysis of Bcl-2, Bax, Bcl-X, and Mcl-1 Expression in Pancreatic Cancers

1999 • 156 citations

PHARMACOKINETICS OF A TUMOR NECROSIS FACTOR-α PHOSPHOROTHIOATE 2′-O-(2-METHOXYETHYL) MODIFIED ANTISENSE OLIGONUCLEOTIDE: COMPARISON ACROSS SPECIES

2003 • 155 citations

Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo.

2000 • 154 citations

bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells

1997 • 153 citations

Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521/CGP 64128A) in patients with cancer.

1999 • 152 citations

Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin.

2002 • 152 citations

Activity of a Novel bcl-2/bcl-xL-Bispecific Antisense Oligonucleotide Against Tumors of Diverse Histologic Origins

2001 • 150 citations

Differential regulation of HSP27 oligomerization in tumor cells grown in vitro and in vivo

2000 • 144 citations

Castration-induced up-regulation of insulin-like growth factor binding protein-5 potentiates insulin-like growth factor-I activity and accelerates progression to androgen independence in prostate cancer models.

2000 • 143 citations

Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies.

1996 • 140 citations

The anti-apoptotic activity of XIAP is retained upon mutation of both the caspase 3– and caspase 9–interacting sites

2002 • 137 citations

Antisense Bcl-2 oligodeoxynucleotides inhibit progression to androgen-independence after castration in the Shionogi tumor model.

1999 • 136 citations

Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells bothin vitroandin vivo

2004 • 133 citations

Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)

1999 • 131 citations

A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancer.

2000 • 128 citations

Overexpression of Insulin-Like Growth Factor Binding Protein-5 Helps Accelerate Progression to Androgen-Independence in the Human Prostate LNCaP Tumor Model through Activation of Phosphatidylinositol 3'-Kinase Pathway

2000 • 128 citations

Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.

2001 • 127 citations

Chemosensitization of Human Renal Cell Cancer Using Antisense Oligonucleotides Targeting the Antiapoptotic Gene Clusterin

2001 • 124 citations

A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.

2002 • 118 citations

Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model.

2001 • 116 citations

Castration-induced increases in insulin-like growth factor-binding protein 2 promotes proliferation of androgen-independent human prostate LNCaP tumors.

2003 • 116 citations

Heat-shock-protein-27(HSP27) expression in ovarian carcinoma: Relation in response to chemotherapy and prognosis

1999 • 113 citations

Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB

2000 • 112 citations

Identification of differentially expressed proteins in human glioblastoma cell lines and tumors

2003 • 111 citations

12(S)-HETE Enhancement of Prostate Tumor Cell Invasion: Selective Role of PKC

1994 • 109 citations

Clusterin: A Role in Cell Survival in the Face of Apoptosis?

1996 • 107 citations

Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence

2002 • 107 citations

Molecular Mechanisms of Antisense Drugs: RNase H

1998 • 106 citations

Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor

2002 • 105 citations

Functional analysis of the human MCL-1 gene

2000 • 105 citations

Do heat shock proteins have a role in breast cancer?

1996 • 101 citations

Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide.

1996 • 100 citations

Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides

1992 • 97 citations

MCL-1 expression in B-cell non-Hodgkin’s lymphomas

2004 • 97 citations

Induction of apoptosis in lung-cancer cells followingbcl-xL anti-sense treatment

2000 • 96 citations

Protein kinase C inhibitors

2002 • 94 citations

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

2003 • 92 citations

A phase I trial of ISIS 2503, an antisense inhibitor of H-ras, in combination with gemcitabine in patients with advanced cancer.

2003 • 90 citations

Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model

2001 • 90 citations

Predicting antisense oligonucleotide inhibitory efficacy: a computational approach using histograms and thermodynamic indices

1992 • 88 citations

A rapid in vitro method for obtaining RNA accessibility patterns for complementary DNA probes: correlation with an intracellular pattern and known RNA structures

1997 • 84 citations

Acute- and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides

1992 • 83 citations

Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma

2004 • 83 citations

Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?

2001 • 78 citations

Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas

2000 • 78 citations

Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed‐backbone antisense oligonucleotides: In vitro and in vivo activities and mechanisms

2002 • 77 citations

Bcl‐X_L is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy

2002 • 76 citations

Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas

1994 • 73 citations

Isolation and characterization of an apoptosis-resistant variant of human leukemia HL-60 cells that has switched expression from Bcl-2 to Bcl-xL.

1996 • 72 citations

BCR-ABL Antisense Oligodeoxynucleotide In Vitro Purging and Autologous Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in Advanced Phase

1998 • 69 citations

Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model

2000 • 69 citations

bcl-xl antisense treatment induces apoptosis in breast carcinoma cells

2000 • 67 citations

Regulation of MDR1 promoter activity in human breast carcinoma cells by protein kinase C isozymes α and θ

2001 • 67 citations

Antisense oligonucleotide inhibitors for the treatment of cancer: 2. Toxicological properties of phosphorothioate oligodeoxynucleotides.

1997 • 63 citations

Induction of p53-Dependent, Insulin-Like Growth Factor-Binding Protein-3-Mediated Apoptosis in Glioblastoma Multiforme Cells by a Protein Kinase Cα Antisense Oligonucleotide

1999 • 62 citations

Antitumor activity of a PKC-alpha antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted into nude mice.

1998 • 60 citations

Antisense Inhibition of Protein Kinase Cα Reverses the Transformed Phenotype in Human Lung Carcinoma Cells

1999 • 58 citations

Mcl-1 Is a Novel Therapeutic Target for Human Sarcoma

2004 • 57 citations

Clusterin and the kidney.

1995 • 54 citations

Oral antisense that targets protein kinase A cooperates with taxol and inhibits tumor growth, angiogenesis, and growth factor production.

2000 • 52 citations

Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-α

1998 • 50 citations

Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.

1997 • 49 citations

Bcl-2 antisense therapy in B-cell malignancies

2005 • 44 citations

Second Generation Antisense Oligonucleotides: 2′-Modifications

1998 • 41 citations

Expression of apoptotic regulators and their significance in cervical cancer

2002 • 40 citations

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

2004 • 39 citations

Bcl-xL antisense oligonucleotides radiosensitise colon cancer cells

2003 • 39 citations

Antisense therapy: current status in prostate cancer and other malignancies.

2002 • 37 citations

Antisense clusterin oligodeoxynucleotides increase the response of HER‐2 gene amplified breast cancer cells to Trastuzumab

2005 • 34 citations

Depletion of protein kinase C (PKC) by 12-O-tetradecanoylphorbol-13-acetate (TPA) enhances platinum drug sensitivity in human ovarian carcinoma cells

2000 • 30 citations

Evaluation of C-5 Propynyl Pyrimidine-Containing OligonucleotidesIn VitroandIn Vivo

2003 • 22 citations

Antisense therapy for cancer.

1998 • 19 citations

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to radical prostatectomy

2004 • 15 citations

Assay for Evaluating Ribonuclease H-Mediated Degradation of RNA–Antisense Oligonucleotide Duplexes

2004 • 10 citations

A phase I pharmacokinetic (PK) and pharmacodynamic (PD) trial of weekly 17-allylamino-17 demethoxygeldanamycin (17AAG, NSC-704057) in patients with advanced tumors

2004 • 4 citations